Business

The South Korean vaccine wave is boosting Asia


South Korea plans to vaccinate three-quarters of its 52 million people against Covid-19 over the next three months as the spread of vaccines by East Asian governments gains momentum following early delays.

Health officials in Seoul on Thursday unveiled plans to expand it Vaccination program a quarter of the population, two weeks ahead of schedule, after vaccination to the general public.

The increase in vaccines comes after Asian countries surpassed Europe և the United States in their initial responses to the coronavirus epidemic. fell back their Western counterparts in supplying and delivering strikes this year.

The struggle in East Asia was attributed to the lack of local manufacturers of Covid vaccines, as well as the inertia of policymakers following their implementation. early success suppressing the virus.

The strong return of export growth և The signs of inflationary pressures are hidden weaker internal restorations Against the background of restrictions on social distance throughout the region և travel, tourism և mass events.

Analysts at the Société Générale described the lack of acceleration in China’s domestic consumption as a “major concern”. The country’s retail and service sectors are still underperforming export recovery set to moderate.

Seoul is in talks with other governments to quickly ease travel restrictions as the vaccine engine gains momentum.

“The decline in the sector – travel, retail, restaurants and hotels – makes it difficult to create a positive cycle for the economy, despite strong exports,” said Park Chong-hun, head of research at Standard Chartered in Seoul.

South Korea will also allow citizens to be vaccinated with various pores as part of a program to address supply shortages and achieve its odor immunity target by November. This means that approximately 760,000 people, including healthcare workers who initially received Oxford / AstraZeneca piercings, may receive their second dose of the BioNTech / Pfizer vaccine.

“Things seem to be going as planned by the government, against small-scale vaccinations by the public,” said Kim Took, professor of infectious disease at Sim Chun Hyang University Hospital.

South Korea’s vaccination rate has surpassed that of neighboring Japan, despite Tokyo rushing to vaccinate its citizens ahead of the July Olympics. Although both countries barely launched their campaigns in April, South Korea’s cumulative dose per capita has jumped to more than 30 in recent days, compared with more than 20 in Aponia.

China, which also had initial delays, provided more than 900 million doses to its 1.4 billion people.

Jeong Yong-kyun, head of the Korea Disease Control and Prevention Agency, said 80 million doses would arrive in South Korea in the third quarter of the year, including 10 million doses in July.

“There is hope for a return to normal life. “But we can not stop the spread of the virus at the current level of vaccination,” said ong yong.

To encourage the vaccine, South Korea is introducing incentives such as allowing vaccinated people to go outside in masks and getting rid of restrictions on gatherings of more than four people. Vaccination sites also apply to companies that have their own medical facilities.

Local trust has been fueled by a number of commercial deals by South Korean biopharmaceutical groups and leading vaccine manufacturers.

SK Bioscience has signed a contract to produce AstraZeneca porous for both domestic and export use. It also signed a license agreement Novavax Produce 40 million units for South Korea, as well as a global supply contract.

Samsung Biologics, the country’s largest pharmaceutical company, plans to start production of Moderna vaccines in the second half of the year for the global market in South Korea, excluding the United States. Another biotechnology company, GL Rapha, will produce doses of Russian Sputnik V for global use.

Additional report by Sherry Fei Ju in Beijing

Coronavirus business update

How does the coronavirus cause harm from markets, businesses, our daily lives, and our workplaces? Stay tuned for more information on our coronavirus newsletter. Register here:



Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button